Skip Navigation


Rheumatology Advance Access originally published online on March 20, 2008
Rheumatology 2008 47(6):753-759; doi:10.1093/rheumatology/ken053
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/6/753    most recent
ken053v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Churchman, S. M.
Right arrow Articles by Ponchel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Churchman, S. M.
Right arrow Articles by Ponchel, F.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

REVIEWS

Interleukin-7 in rheumatoid arthritis

S. M. Churchman and F. Ponchel

The University of Leeds, Leeds Institute of Molecular Medicine, Section of Musculoskeletal Disease, St James's University Hospital, Leeds, UK.

Correspondence to: F. Ponchel, The University of Leeds, Leeds Institute of Molecular Medicine, Section of Musculoskeletal Disease, St James's University Hospital, Leeds, LS9 7TF, UK. E-mail: f.ponchel{at}leeds.ac.uk; mmefp{at}leeds.ac.uk


  Abstract

Recent data from several groups demonstrate high levels of IL-7 in the joints of RA patients, but much lower levels in OA. In contrast, circulating levels of IL-7 in RA remain a point of debate. IL-7 has many roles in T cell, dendritic cell and bone biology in humans. Reduced levels of circulating IL-7 probably underlie a number of the dysfunctions associated with circulating T cells in RA and may provide a mechanism for some of the unexplained systemic manifestations of the disease. However, IL-7 in the joint may have a more sinister role, contributing to a vicious cycle perpetuating inflammation. Typically, IL-1β and TNF-{alpha} increase the stromal production of IL-7 and in turn, IL-7 up-regulates the production of TNF-{alpha} by macrophages. Most importantly, IL-7 induces the production of osteoclastogenic cytokines by T cells, leading to the maturation of osteoclasts and therefore bone destruction. By linking the stroma with innate and adaptive immunity in RA, IL-7 may be directing the cellular network, leading to chronic inflammation and joint destruction. Blocking IL-7 may well therefore be of therapeutic value.

KEY WORDS: IL-7, RA, Inflammation, T cells

Submitted 19 July 2007; revised version accepted 23 January 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.